Clinical trial
The Efficacy and Safety of Levocetirizine Dihydrochloride Oral Drops Given 0.125 mg/kg b.i.d. During 90 Days in the Treatment of Recurrent Cough Associated With Other Allergic Symptoms, e.g. Wheezing, in Children Aged 1-2 Years.
NCT00520754 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Levocetirizine Dihydrochloride Oral Drops Given 0.125 mg/kg b.i.d. During 90 Days in the Treatment of Recurrent Cough Associated With Other Allergic Symptoms, e.g. Wheezing, in Children Aged 1-2 Years.
- Lead sponsor
- UCB Pharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2001
- Completion date
- March 31, 2003
- Enrollment
- 15 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.